Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.65 |
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4505873 | 0.91 | KMT2A (0.64) | KMT2AMEN1ALDH1A1PIP4K2ALMNA | |
| SCHEMBL21504938 | 0.91 | KMT2A (0.58) | KMT2AMEN1ALDH1A1PIP4K2ALMNA | |
| SCHEMBL4515693 | 0.89 | KMT2A (0.80) | KMT2AMEN1ALDH1A1PIP4K2ALMNA | |
| SCHEMBL4519704 | 0.89 | KMT2A (0.79) | KMT2AMEN1ALDH1A1PIP4K2ALMNA | |
| SCHEMBL4507208 | 0.88 | KMT2A (0.51) | KMT2AMEN1ALDH1A1PIP4K2ALMNA | |
| SCHEMBL4518657 | 0.88 | KMT2A (0.51) | KMT2AMEN1ALDH1A1PIP4K2ALMNA | |
| SCHEMBL3491664 | 0.87 | RNASEH1 (0.58) | KMT2AMEN1ALDH1A1PIP4K2ALMNA | |
| SCHEMBL4514858 | 0.87 | KMT2A (0.67) | KMT2AMEN1ALDH1A1PIP4K2ALMNA | |
| SCHEMBL4518642 | 0.87 | PIP4K2A (0.66) | KMT2AMEN1ALDH1A1PIP4K2ALMNA | |
| SCHEMBL38376 | 0.86 | RNASEH1 (0.52) | KMT2AMEN1ALDH1A1PIP4K2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139499-A1 | MEGLUMINE SALTS OF THIENOPYRIMIDINES | CARDURION PHARMACEUTICALS LLC (US) | 2021-05-13 | — | — | US | disclosed |
| EP-3781155-A1 | MEGLUMINE SALTS OF THIENOPYRIMIDINES | Cardurion Pharmaceuticals, LLC (US) | 2021-02-24 | — | — | EP | disclosed |
| US-10822346-B2 | Meglumine salts of thienopyrimidines | CARDURION PHARMACEUTICALS, LLC (US) | 2020-11-03 | — | — | US | disclosed |
| WO-2019204298-A1 | MEGLUMINE SALTS OF THIENOPYRIMIDINES | CARDURION PHARMACEUTICALS, LLC (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20190315765-A1 | MEGLUMINE SALTS OF THIENOPYRIMIDINES | CARDURION PHARMACEUTICALS LLC (US) | 2019-10-17 | — | — | US | disclosed |
| US-9006253-B2 | Crystal of 2-(3,4-dichlorobenzyl)-5-methyl-4-oxo-3,4-dihydrothieno[2,3-D]pyrimidine-6-carboxylic acid | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-04-14 | — | — | US | disclosed |
| EP-2594570-B1 | CRYSTAL OF THIENOPYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2015-02-25 | — | — | EP | disclosed |
| EP-1908765-B1 | THIENOPYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2014-10-22 | — | — | EP | disclosed |
| US-20140235655-A1 | CRYSTAL OF THIENOPYRIMIDINE DERIVATIVE | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2014-08-21 | — | — | US | disclosed |
| US-8748437-B2 | Crystal of 2-(3,4 dichlorobenzyl)-5-methyl-4-oxo-3,4-dihydrothien[2,3-D]pyrimidine-6-carboxylic acid | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2014-06-10 | — | — | US | disclosed |
| EP-2594570-A1 | CRYSTAL OF THIENOPYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-20130123279-A1 | CRYSTAL OF THIENOPYRIMIDINE DERIVATIVE | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-05-16 | — | — | US | disclosed |
| US-8377944-B2 | Thienopyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20130023546-A1 | THIENOPYRIMIDINE DERIVATIVES | GOTANDA KOTARO (JP) | 2013-01-24 | — | — | US | disclosed |
| US-8293754-B2 | Thienopyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20090203703-A1 | Thienopyrimidine Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-1908765-A1 | THIENOPYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822346-B2 | Meglumine salts of thienopyrimidines | DPYD, TPMT, TYMP | KMT2A 3203/4885MEN1 1155/4885ALDH1A1 265/4885 |
| US-20130023546-A1 | THIENOPYRIMIDINE DERIVATIVES | PDE9A, BPHL, THOP1 | KMT2A 2650/4885MEN1 2509/4885ALDH1A1 2303/4885 |
| US-20140235655-A1 | CRYSTAL OF THIENOPYRIMIDINE DERIVATIVE | PDE9A, PDE7A, PDE12 | KMT2A 3057/4885MEN1 4600/4885ALDH1A1 633/4885 |
| US-20190315765-A1 | MEGLUMINE SALTS OF THIENOPYRIMIDINES | DPYD, TPMT, TYMP | KMT2A 3203/4885MEN1 1155/4885ALDH1A1 265/4885 |
| US-20090203703-A1 | Thienopyrimidine Derivatives | PDE9A, BPHL, THOP1 | KMT2A 2650/4885MEN1 2509/4885ALDH1A1 2303/4885 |
| US-20210139499-A1 | MEGLUMINE SALTS OF THIENOPYRIMIDINES | DPYD, TPMT, TYMP | KMT2A 3203/4885MEN1 1155/4885ALDH1A1 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.